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HER-2/neu oncoprotein contains several major histocompatibility complex class I-restricted epitopes, which are recognised by
cytotoxic T lymphocyte (CTL) on autologous tumours and therefore can be used in immune-based cancer therapies. Of these, the
most extensively studied is HER-2(9369). In the present report, we used dendritic cells pulsed with HER-2(9369) to stimulate, in the
presence of IL-7 and IL-12, the production of IFN-g by patients’ CTL detected by the enzyme-linked immunosorbent spot-assay.
Frequencies of peptide-specific precursors were estimated in HLA-A2, HLA-A3 and HLA-A26 patients with HER-2/neu-positive (þ)
breast, ovarian, lung, colorectal and prostate cancers and healthy individuals. We found increased percentages of such precursors in
HLA-A2 (25%) and HLA-A26 (30%) patients, which were significantly higher (60%) in HLA-A3 patients. Our results demonstrate for
the first time that pre-existing immunity to HER-2(9369) occurs in patients with colorectal, lung and prostate cancer. They also suggest
that HER-2(9369) can be recognised by CTL, besides HLA-A2, also in the context of HLA-A3 and HLA-A26, thus increasing the
applicability of HER-2(9369)-based vaccinations in a considerably broader patients’ population.
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The HER-2/neu protein is a member of the tyrosine kinase family
of growth factor receptors (Coussens et al, 1985; Bargmann et al,
1986). It is frequently amplified and overexpressed in breast
(Slamon et al, 2001), ovarian (Slamon et al, 1987), pancreatic
(Yamanaka et al, 1993) and colorectal (Maxwell-Armstrong et al,
1998) carcinomas and in other types of cancer (Slamon et al, 1987;
Scher, 2000), for which overexpression often correlates with a poor
prognosis. HER-2/neu is an immunogenic protein because some
patients whose tumours overexpress HER-2/neu have pre-existing
antibody and T-cell immunity directed against this antigen
(Disis and Cheever, 1997). In addition, cytotoxic T lymphocyte
(CTL) responses against HER-2/neu
þ tumours have been induced
in vitro using major histocompatibility complex (MHC) class
I-binding synthetic peptides derived from the HER-2/neu
sequence (Fisk et al, 1995; Linehan et al, 1995; Brossart et al,
1998; Rongcun et al, 1999; Baxevanis et al, 2002). The identifica-
tion of multiple MHC class I-restricted HER-2/neu-specific CTL
epitopes will allow the selection of the epitope with the highest
potential for vaccination. Such epitopes must be highly immuno-
genic and must be able to recruit a wide spectrum of high avidity
functional CTL, capable of generating effective antitumour
responses.
The HER-2/neu epitope, spanning amino acids 369–377 (HER-
2(9369)), was first described by Fisk et al (1995) as an
immunodominant human leucocyte antigen (HLA)-A2-restricted
epitope that was recognised by four out of four ovarian tumour-
associated lymphocytes, as well as tumour reactive clones. HER-
2(9369) represents a common epitope expressed by various tumour
types including ovarian (Kono et al, 1997; Rongcun et al, 1999),
renal cell (Brossart et al, 1998; Seliger et al, 2000) and breast
(Brossart et al, 1998) carcinomas and melanoma cells (Rongcun
et al, 1999). Tumour cell lines endogenously processing and
expressing HER-2(9369) in the context of HLA-A2, could be
efficiently recognised by the HER-2(9369)-specific CTL (Fisk et al,
1995; Rongcun et al, 1999; Baxevanis et al, 2002). In addition,
splenocytes from human-CD8 and HLA-A2 transgenic mice that
were vaccinated with HER-2(9369) recognised human tumour cell
lines expressing both HLA-A2 and HER-2/neu (Lustgarten et al,
1997). Vaccination of HLA-A2
þ and HER-2/neu
þ cancer patients
with the helper peptide HER-2(15369), which contains the HER-
2(9369) CTL epitope, resulted in increased frequencies of HER-
2(9369) precursors and generated CD8
þ CTL responses against
tumour cell lines naturally expressing or pulsed to express HER-
2(9369) (Knutson et al, 2001). In a more recent report, Knutson et al
(2002) showed that immunisation of four patients with breast or
ovarian cancer with HER-2(9369) plus GM-CSF resulted in
increased peptide-specific T-cell precursor frequencies (PF) in
two of them. Active immunisation of patients with HER-2/neu
peptide-based vaccines (also including HER-2(15369)) generated
immunity to HER-2/neu peptides and to HER-2/neu intracellular
and extracellular domains (Disis et al, 2002). In the same study,
patients who received a vaccine consisting of the helper peptides Received 25 March 2003; revised 2 June 2003; accepted 8 July 2003
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T-cell response to HER-2(15369) but not to the other peptides in
the immunising mix, demonstrating the immunodominance of
HER-2(15369). In our recent work (Baxevanis et al, 2002), by
applying a CTL induction protocol using patients’ dendritic cells
(DC) pulsed with total peptide extracts from autologous HER-2/
neu
þ tumours, we could also demonstrate an immunodominance
of HER-2(9369) in the tumour-specific CTL repertoire of the
patients.
Although the immunogenicity of HER-2(9369) has been merely
shown in studies aiming at generation of peptide-specific CTL in
vitro, and also in vivo, in the course of vaccination protocols
assessing the efficacy of the HER-2/neu peptide vaccines, very low
PF to this peptide could be detected in HER-2/neu-overexpressing
HLA-A2 patients (Disis et al, 2000; Knutson et al, 2001). Given the
fact that HER-2(9369) binds with high affinity to HLA-A2 allele, we
assumed that T-cell clones recognising this particular bimolecular
complex (i.e., HLA-A2þHER-2(9369)) might have been partially
tolerised, suggesting that boosting or generating an immune
response via immunisation could represent a reasonable approach
for reactivating such clones. Alternatively, binding of HER-2(9369)
to alleles other than HLA-A2 allele(s) with intermediate- or low-
binding scores would possibly lead to the generation of
intermediate- or low-affinity CTL clones not tolerised by the
immune apparatus. With regard to the first possibility, Knutson
et al (2002) demonstrated that HLA-A2 patients immunised with
HER-2(15369) could develop IFN-g enzyme-linked immunosorbent
spot (ELISPOT) responses to HER-2(9369) and also exhibited
increased HER-2(9369)-specific PF. Investigating the second
possibility using computer algorithms (SYFPEITHI, www.uni-
tuebingen.de/uni/kxi/database.html; Rammensee et al, 1999), we
found that HER-2(9369), in addition to HLA-A2, also binds to HLA-
A26 and HLA-A3 alleles with high- (similar to HLA-A2) and
intermediate-affinity scores, respectively. Therefore, we thought
that it might be important to analyse peptide-specific CTL
frequencies in patients with HER-2/neu
þ tumours expressing
these alleles. Besides the binding affinity between peptide and
HLA alleles that possibly determine patients’ CTL repertoire
in vivo, an important factor that may influence the determination
of PF of ex vivo peptide-specific CTL is the short-term in vitro
stimulation protocol used for detecting peptide-specific
cytokine production in ELISPOT assays (Disis et al, 2000;
Knutson et al, 2002). To this end, we used a novel protocol to
activate patients’ T lymphocytes for evaluating IFN-g in the
ELISPOT assay. This included mature DC, generated from patients’
monocytes, which were pulsed with HER-2(9369) and used, in the
presence of IL-7 and IL-12, to stimulate IFN-g production by the
autologous peripheral blood mononuclear cells (PBMC). By
applying this protocol, we have been able to detect HER-2(9369)
peptide-specific CTL precursors at high frequencies within PBMC
developed mostly in HLA-A3 patients, whereas lower frequencies
of the same precursors could be detected in HLA-A2 or HLA-A26
patients.
PATIENTS AND METHODS
Patients
Patients with histologically confirmed breast, ovarian, lung,
colorectal and prostate carcinomas were included in this study
(see also Table 1). Peripheral blood mononuclear cells were
collected from peripheral blood samples. Biologic material was
provided by the Breast Cancer Clinic of Saint Savas Cancer
Hospital and the Department of Pathophysiology of Laikon
General Hospital under the Institutional Review Board of both
institutions. All volunteers provided informed consent before
entering these studies.
Isolation of PBMC
Peripheral blood mononuclear cells were isolated by density
gradient centrifugation using Ficoll Separating Solution (Biochrom
AG, Berlin, Germany). Cells were washed twice with phosphate-
buffered saline (PBS) and used immediately or kept frozen until
use.
HLA-genotyping
Total RNA was extracted from patients’ and healthy donors’ PBMC
using the SV Total RNA Isolation System (Promega, Madison,
USA), according to the manufacturer’s protocol. First-strand
cDNA synthesis was performed using approximately 2mg of total
RNA, oligodT primers and the SuperScript II Rnase H ( ) reverse
transcriptase (Invitrogen, Carlsbad, USA). This cDNA material was
used for PCR amplification with Taq Platinum (Invitrogen) using
the PROTRANS Cyclerplate System HLA class I and HLA class II
(Protrans, Ketsch, Germany) according to the manufacturer’s
instructions. The typing results were obtained after electrophoresis
of the amplification products on 2% agarose gel containing GelStar
dye (FMC BioProducts Rockland, ME, USA) and visualised by UV
light. Individuals expressing HLA-A2, HLA-A3 or HLA-A26 alleles
or a combination of either were enrolled in this study.
Peptide synthesis
HER-2 (369–377) (KIFGSLAFL) peptide was synthesised by the
solid-phase method with an Ecosyn P peptide synthesiser
(Eppendorf-Biotronik, Hamburg, Germany) using the Fmoc
strategy and a 4-carboxybenzyl alcohol resin. Purification was
performed by high-performance liquid chromatography. The
purity was 495%. Quantitative and qualitative determination
were controlled by amino-acid analysis and matrix-assisted laser
desorption mass spectrophotometry (Kratos Kompact Maldi II,
Kratos Analytical, Manchester, UK). Peptide was lyophilised,
dissolved in PBS, aliquoted at 2mgml
 1 and stored frozen at
 201C until use.
Monoclonal antibodies (Abs) and immunophenotyping
The expression of HER-2/neu on tumour cells was determined
using the PE-conjugated anti-HER-2/neu monoclonal antibody
(mAb) (clone Neu 24.7), which recognises the extracellular domain
of HER-2/neu (Becton Dickinson, Mountain View, CA, USA).
When malignant effusions were available, the expression of HER-
2/neu was determined by flow cytometry comparing the mean
fluorescence intensity (MFI) of the tumour cells with the MFI of
tumour cell lines expressing HER-2/neu at different levels (HER-2/
neu expression of the MDA-231 cell line is scored as 1, of MCF-7 as
2 and of SKBR-3 as 3). The expression of HER-2/neu on solid
tumours was performed by immunohistochemistry by estimating
the number and intensity of stained tumour cells per section of
tumour specimen as previously reported (Berger et al, 1989) and
using the DAKO’s 0–3 scoring system. For DC typing the following
mAb were used: anti-CD83 conjugated with PE mAb, obtained
from Caltag Laboratories (Burlingame, CA, USA); anti-CD16,
-CD20, -CD40 and -CD80 conjugated with FITC and anti-CD3,
-CD14, -CD86 and anti-HLA-DR conjugated with PE, purchased
from PharMingen (San Diego, CA, USA). Cells to be immunos-
tained were washed twice with ice-cold PBS/1% fetal bovine serum
(FBS, Life Technologies, Gaithersburg, MD, USA) followed by
incubation with saturating concentrations of the appropriate mAb
for 20min at room temperature. Thereafter, cells were washed
twice in ice-cold PBS/1% FBS and fixed with 1% paraformaldehyde
in PBS. Samples were analysed using FACSCalibur (Becton
Dickinson) and CellQuest analysis software.
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Dendritic cells were generated from CD14
þ monocyte precursors
purified from freshly isolated PBMC by positive immunoselection
using an anti-CD14mAb coupled onto magnetic microbeads
(Miltenyi Biotech, Auburn, CA, USA) under the manufacturer’s
protocol. Monocyte differentiation in DC was performed as
described (Sotiriadou et al, 2001). In brief, the CD14
þ cells were
cultured in 2ml X-VIVO 15 medium (BioWhittaker Europe,
Belgium) supplemented with 1% autologous heat-inactivated
plasma, 1000IUml
 1 IL-4 (R&D Systems, Europe) and
1000IUml
 1 GM-CSF (Immunex, Seattle, WA, USA). Fresh
medium (2ml) with cytokines was added on days 2 and 4.
Tumour necrosis factor-a (R&D Systems) was added at 10ngml
 1
on day 6. Dendritic cells were harvested on day 7 and used as
antigen-presenting cells (APC) or cryopreserved for later use. The
Table 1 Patients enrolled in this study
Patient no. Age (years) Sex Type of Ca Stage HLA-A HER-2/neu expression
a Source of Ca cells
1 57 F Breast III HLA-A2 1 Solid tumour
2 56 F Ovarian III HLA-A2 2 Solid tumour
3 63 M Colorectal III HLA-A2 1 Solid tumour
4 79 F Breast IV HLA-A2 3 Effusion
5 55 F Breast III HLA-A2 1.5 Solid tumour
6 45 F Breast IV HLA-A2, -A3 2 Effusion
7
b 47 M Prostate IV HLA-A2 1 Effusion
8 58 F Breast III HLA-A2 2.5 Solid tumour
9 69 F Ovarian IV HLA-A2 2 Solid tumour
10 72 M Lung IV HLA-A2 1 Effusion
11 64 M Colorectal III HLA-A2 2 Effusion
12 55 F Breast II HLA-A2 2 Solid tumour
13 50 F Colorectal III HLA-A2 1 Solid tumour
14 38 F Lung IV HLA-A2 2.5 Effusion
15 45 F Ovarian IV HLA-A2 1.5 Effusion
16 44 F Ovarian III HLA-A2 2 Solid tumour
17 57 F Breast III HLA-A3, -A26 3 Solid tumour
18
b 62 F Breast IV HLA-A3 2 Effusion
19 75 F Ovarian III HLA-A3 2 Solid tumour
20 67 M Lung IV HLA-A3 1.5 Effusion
21 59 F Ovarian IV HLA-A3 2 Effusion
22 39 F Lung IV HLA-A3, A26 1 Effusion
23 62 M Prostate IV HLA-A3 1 Solid tumour
24 75 F Breast III HLA-A3 3 Solid tumour
25 68 F Breast III HLA-A3 1.5 Solid tumour
26
b 62 F Breast IV HLA-A26 2 Effusion
27 79 F Ovarian III HLA-A26 1.5 Solid tumour
28 78 F Ovarian IV HLA-A26 2 Effusion
29 65 M Lung III HLA-A26 2.5 Effusion
30 47 M Colorectal III HLA-A26 1.5 Solid tumour
31 49 F Ovarian III HLA-A26 2 Solid tumour
32 57 F Breast IV HLA-A26 3 Effusion
33 57 F Breast III HLA-A2 0 Solid tumour
34 73 F Breast IV HLA-A2, -A3 0 Effusion
35 63 F Breast III HLA-A2 0 Solid tumour
36 72 F Breast III HLA-A2 0 Solid tumour
37 55 M Lung IV HLA-A2 0 Effusion
38 39 F Ovarian III HLA-A2 0 Solid tumour
39 64 M Prostate IV HLA-A2 0 Effusion
40 54 M Lung IV HLA-A2 0 Effusion
41 57 F Colorectal III HLA-A2 0 Solid tumour
42 65 M Colorectal III HLA-A2 0 Solid tumour
43 75 F Breast III HLA-A2 0 Solid tumour
44 63 F Ovarian IV HLA-A2 0 Effusion
45 72 F Ovarian III HLA-A3 0 Solid tumour
46 57 F Ovarian IV HLA-A3 0 Effusion
47 59 F Breast III HLA-A3 0 Solid tumour
48 65 M Lung III HLA-A3 0 Solid tumour
49 47 M Prostate III HLA-A3 0 Solid tumour
50 59 F Ovarian III HLA-A3 0 Solid tumour
51 75 F Breast III HLA-A3 0 Solid tumour
52 69 F Breast IV HLA-A26 0 Effusion
53 75 F Ovarian III HLA-A26 0 Solid tumour
54 73 F Ovarian III HLA-A26 0 Solid tumour
55 59 F Breast IV HLA-A26 0 Solid tumour
56 38 M Prostate IV HLA-A26 0 Effusion
57 39 M Lung III HLA-A26 0 Effusion
58 67 M Colorectal III HLA-A26 0 Solid tumour
aDetermined by flow cytometry in effusions and by immunohistochemistry in solid tumours (see also ‘Materials and Methods’).
bPatient homozygous for this allele.
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expression of a CD3
 , CD14
 , CD16
 , CD20
 , CD40
þ, CD80
þ,
CD83
þ, CD86
þ and HLA-DR
þ phenotype analysed by flow
cytometry (Perez et al, 2003). Dendritic cells were used as APC
pretreated with 100mgml
 1 mitomycin C (Kyowa, Tokyo, Japan)
for 45min at 371C. Following an extensive wash in Hank’s
balanced salt solution (Life Technologies), DC were pulsed with
50mgml
 1 of the peptide for 4h at 371C.
Enzyme-linked immunosorbent spot assay
The ELISPOT assay was used to determine PF of HER-2(9369)-
specific CTL. On day 0, PBMC from every individual were plated at
500000well
 1 in quadruplicates in 96 flat-bottom well plates.
Autologous DC pulsed with 50mgml
 1 of peptide HER-2(9369)
were added to PBMC at a cell ratio of 1:10 in a total volume of
200mlwell
 1 X-VIVO 15 medium supplemented with 1% auto-
logous heat-inactivated plasma, 10ngml
 1 human recombinant
IL-7 and 100pgml
 1 human recombinant IL-12 (both purchased
from R&D systems). Control cultures contained PBMC, stimulated
with unpulsed DC or DC pulsed with soluble tetanus toxoid (TT)
(Ladecle Laboratories, Pearl River, NY, USA) at 0.1LFUml
 1.
Cultures were incubated at 371Ci naC O 2 incubator. On day 3,
100ml of the culture supernatant was decanted and replaced by an
equal volume of fresh medium supplemented with 20ngml
 1 IL-7
and 200pgml
 1 IL-12. Growing microcultures were restimulated
on day 7 with DC pulsed with the same concentration of the
peptide or TT. After 24h, IFN-g production was estimated using
the Biosource IFN-g ELISPOT-assay kit (Biosource International,
Camarillo, CA, USA) under the manufacturer’s protocol. Spots
were counted under a stereomicroscope (Zeiss, Germany) using
Image ProPlus software (Media Cyhernetics Silver Spring, MD,
USA). Specific precursors were calculated by subtracting the mean
number of spots obtained from the control cultures (i.e., with
unpulsed DC) plus two s.d. from the mean number obtained in the
experimental cultures (with peptide-pulsed or TT-pulsed DC).
Precursor frequencies were evaluated as the number of specific
precursors per 10
6 PBMC
 1. Precursor frequencies to HER-2(9369)
were also enumerated from PBMC from patients with HER-2/neu
negative (
 )tumours and healthy individuals. We considered as
responders those HER-2/neu
þ patients whose individual PF were
significantly higher from the mean PF in these two groups.
Proliferation assay
Proliferative responses to phytohaemagglutinin (PHA) (Sigma)
were performed as previously described (Baxevanis et al, 1990).
Data are presented as stimulation index (i.e., counts per min
(c.p.m.) from PBMC cultures with PHA divided by c.p.m. from
PBMC cultures without PHA).
Statistical analysis
Significant differences between individual PF in HER-2/neu
þ
patients with the mean PF in HER-2/neu
  patients or healthy
donors were assessed by applying t-test statistics. Significant
differences between the mean PF among groups were also assessed
by the t-test.
RESULTS
Patients expressing HLA-A2 (n¼28), HLA-A3 (n¼18) or HLA-
A26 (n¼16) were investigated (Table 1). The median time from
last chemotherapy was 6 months (range 3–19). Of the breast
cancer patients, 13 were diagnosed with stage III disease, 10 with
stage IV and one with stage II. Of the ovarian cancer patients, 10
had stage III and six had stage IV disease. All colorectal cancer
patients (n¼7) had stage III disease, whereas of the lung Ca
patients, three had stage III and seven of them had stage IV
disease. Finally, four patients with prostate cancer were diagnosed
as having a stage IV disease and one stage III.
Patients enrolled in the study were examined for immunocom-
petence using IFN-g ELISPOT analysis evaluating the PF to whole
TT. Proliferative responses upon stimulation with PHA in the same
patients were also estimated. In addition, the HER-2(9369)-specific
T-cell PF were examined in heterozygous HLA-A2 (n¼10), HLA-
A3 (n¼7) and HLA-A26 (n¼7) healthy donors. Four of 16 (25%)
HLA-A2 patients (nos. 5, 6, 8 and 12) whose tumours over-
expressed HER-2/neu demonstrated CTL immunity to HER-2(9369)
(range of PF¼25.1–37.7; mean PF¼30.0, (Figure 1)) (Po0.001
compared to mean PF from HER-2/neu
  patients and healthy
donors). The rest of HLA-A2, HER-2/neu
þ patients (n¼12; 75%)
were nonresponders, demonstrating low frequencies of peptide-
specific CTL (range of PF¼0–11.7; mean PF¼7.1, Po0.01
compared to mean PF of the four responders), which were almost
comparable with those (mean PF) observed in the group of HLA-
A2 patients with HER-2/neu
  tumours (range of PF¼0–11.8;
mean PF¼5.5) (Figure 1) and of HLA-A2 healthy volunteers (in
both cases P: nonsignificant (NS)). The frequencies for TT did not
differ significantly among patients and healthy donors
(range¼100.0–476.0; mean: 230.4 for patients and
range¼108.1–512.8; mean: 170.4 for healthy donors) (P¼0.25).
The magnitude of responses to PHA was also comparable among
patients and healthy donors (Data not shown).
The majority of HER-2/neu-overexpressing HLA-A3 patients
displayed pre-existing CTL immunity to HER-2(9369). As presented
in Figure 1, six of 10 patients examined (nos. 6, 17, 18, 19, 22
and 23) demonstrated increased peptide-specific CTL PF
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Figure 1 HER-2(9369) PF in patients with HER-2/neu
þ or HER-2/neu
 
tumours and healthy individuals. Above the dotted line responders to the
peptide are shown. The solid lines indicate the mean PF for each group. (A)
HLA-A2
þ donors, (B) HLA-A3
þ donors and (C) HLA-A26
þ donors.
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patients in this group exhibited low pre-existing CTL PF to
HER-2(9369) (PF range ¼ 0–10.5; mean PF¼4.7, Po0.001),
which were at almost similar levels with those observed from
the groups of HLA-A3, HER-2/neu
  patients (range¼0–10.5;
mean PF¼4.5) and of healthy donors (range¼0–8.1; mean
PF¼4.1) (Figure 1). As with HLA-A2 patients, also in this group,
responses to TT and PHA were comparable with those of healthy
donors (Data not shown).
Finally, we examined HLA-A26 patients with HER-2/neu-over-
expressing tumours. Three of nine patients (nos. 17, 22 and 30;
30%) displayed high CTL PF to HER-2(9369), ranging from 11.3 to
25.1 (mean PF¼21.4), which differed significantly (Po0.001) from
the PF detected in the residual six nonresponder patients (PF
range¼0–10.1; mean PF¼5.7). These patients along with the
seven patients with HER-2/neu
  tumours and the seven healthy
donors exhibited PF to HER-2(9369), which did not differ
statistically when compared to each other (PF range and mean
PF in HER-2/neu
  patients: 0–10.2 and 4.5; and in healthy donors:
0–9.7 and 4.4, respectively). Responses to TT and PHA were
similar in all individuals tested (Data not shown).
Finally, by comparing the PF mean values in the group of total
HER-2/neu
þ patients with those observed in HER-2/neu
 
patients, we found statistically significant differences as follows:
HLA-A2
þ HER-2/neu
þ vs HLA-A2
þ HER-2/neu
 , Po0.05; HLA-
A3
þ HER-2/neu
þ vs HLA-A3
þ HER-2/neu
 , Po0.01; HLA-A26
þ
HER-2/neu
þ vs HLA-A26
þ HER-2/neu
 , Po0.05.
DISCUSSION
This study provides evidence for the existence of an in vivo T-cell
response to HER-2(9369) in patients with advanced cancer whose
tumours overexpress HER-2/neu. Furthermore, our study supports
two other points. It demonstrates for the first time that HER-2/neu
is a tumour antigen recognised by CTL in prostate cancer patients.
Indeed, our HLA-A2, three patients with prostate cancer demon-
strated an increased HER-2(9369)-specific PF of CTL among PBMC
in the IFN-g ELISPOT assay. Second, our results suggest that the
HER-2(9369) peptide, besides HLA-A2, is also recognised by CTL in
the context of two other alleles, namely HLA-A3 and HLA-A26,
besides in breast and ovarian cancer patients and also in patients
with colorectal, lung and prostate cancer.
A minority of HLA-A2 patients (four of 16; 25%) and of HLA-
A26 patients (three of nine; 30%) with HER-2/neu overexpressing
cancers in advanced stages had detectable pre-existent CD8
þ T-
cell responses directed against HER-2(9369) (in all cases, the
frequencies ranged between 31.7 and 17.3). In contrast,
the majority of patients with HER-2/neu
þ tumours carrying the
HLA-A3 allele (six of 10; 60%) responded with increased PF to this
peptide (range¼13.9–29.9). One of the four responders in the
HLA-A2 group of patients (Table 1) and two of three responders in
the group of patients expressing the HLA-A26 allele (Table 1) also
expressed HLA-A3. Taking into consideration the overall re-
sponses we obtained, it may be more likely that in these particular
cases HLA-A3 would represent the restricting element. Alterna-
tively, these patients may respond to HER-2(9369) by virtue of two
different sets of T-cell clones restricted by HLA-A2 or HLA-A26
and HLA-A3 alleles.
T cells of HLA-A2 and HLA-A26 patients expressing HER-2/neu
had the ability to respond to antigenic stimuli as evidenced by the
PHA response, which was comparable with those in the group of
HLA-A3 patients, exhibiting high percentages of donors with
peptide-specific pre-existent immunity, and in the group of
healthy donors. Furthermore, this study group had a similar
incidence of immune responses to TT as described in the
population of healthy donors. Thus, one reason that may account
for the low numbers of peptide-specific responders in the groups
of HLA-A2 and HLA-A26 patients is that HER-2(9369) has a high
binding score to the HLA-A2 and HLA-A26 alleles, whereas it
binds only with intermediate affinity to HLA-A3 (Database
SYFPEITHI; Rammensee et al, 1999). Consequently, during natural
immunogenic processing of the intact HER-2/neu protein, HER-
2(9369) may be presented in the context of HLA-A2 or HLA-A26 in
an immunodominant manner and be recognised by high-affinity
CD8
þ T-cell clones, which will be tolerised by the immune system
in order to prevent the induction of an immune response to
nonmalignant epithelial cells also expressing HER-2/neu.
Indeed, dominantly processed self-determinants are thought to
be efficient in tolerance induction (Nanda and Secarz, 1995;
Sercarz, 2000).
Conversely, the high percentages of HER-2(9369)-specific pre-
cursors that we observed in HLA-A3 patients may be explained by
the fact that, due to its capacity to bind with intermediate affinity
to this particular allele, HER-2(9369) may be recognised by low-
affinity CD8
þ T-cell clones. Such clones are not tolerised, because
they will not recognise basal levels of HER-2/neu expressed in the
normal epithelium. However, the abundance of this peptide-
epitope in HLA-A3 molecules expressed either on syngeneic
tumour cells or HER-2(9369)-pulsed syngeneic DC will activate
these clones to produce cytokines (e.g. IFN-g) and lyse their
specific targets.
The state of tolerance to self-antigens may be circumvented in
vivo by peptide-based vaccinations or in vitro by repetitive
restimulations with peptide-pulsed autologous DC, as has been
already shown for melanoma differentiation antigens (Jager et al,
2002) and also HER-2/neu. With respect to the latter, most of
HLA-A2 breast cancer patients with HER-2/neu-overexpressing
tumours receiving monthly injections with the helper peptide
HER-2(15369), which contains within the putative HLA-A2-binding
motif HER-2(9369), developed, after immunisation, CD8
T-cell responses to peptide HER-2(9369) (10 of 15 patients tested;
66.6%) (Knutson et al, 2001). Before immunisation only two of 15
(i.e., 13.33%) expressed pre-existent immunity to this peptide
(Knutson et al, 2001). A similar situation was reported by Disis et al
(2002), where the vast minority of HLA-A2 patients had
pre-existent immune responses to HER-2(9369) (two of 38; 5%),
whereas the majority of these patients developed peptide-specific
immunity upon stimulation with HER-2(15369). More
strikingly, breast and ovarian cancer patients immunised with
HER-2(9369) developed T-cell precursors specific for this peptide
(Knutson et al, 2002). Since in these immunisation protocols
patients enrolled expressed HLA-A2, it remains to be examined
whether a similar situation will also appear with HLA-A26 and
HLA-A3 patients.
Our results demonstrate higher percentages (25%) of HLA-A2
patients with pre-existing immunity to HER-2/neu peptide
compared to those (i.e., 13.33, 5 and 0%) reported by others
(Disis et al, 2000, 2002; Knutson et al, 2001). Since an IFN-g
ELISPOT assay was used to determine PF of peptide-specific
CD8
þ T lymphocytes, we believe that the differences in our and
their protocols may account for such discrepancies. First of all, we
must point out the fact that we, as they also did, estimated PF from
PBMC and not isolated CD8
þ T cells. However, since it is well
established that HER-2(9369) is recognised by MHC class I-
restricted CD8
þ CTL (as it is the case with peptides consisting
of 8–10 aminoacids) (Fisk et al, 1995; Brossart et al, 1998;
Rongcun et al, 1999; Baxevanis et al, 2002), we can be sure that we
measured CD8
þ T-cell PF. Regarding culture conditions during
the incubation period, it is essential to note that we used
autologous DC (instead of PBMC) as peptide-presenting cells in
the presence of exogenously added IL-7 and IL-12 (instead of IL-2)
both of which are known to support antigen-specific CD8
þ T-cell
responses (Costello et al, 1993; Trinchieri, 1995, 1997). In this way,
we may have established a culture system favouring the detection
of pre-existing CD8
þ T cell-mediated responses, eventually also in
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immunologic tolerance.
To this end, it is important to mention that preliminary
experiments performed in our laboratory demonstrated the
capacity of cultures with high peptide-specific CTL PF to lyse
autologous peptide-pulsed, but not unpulsed DC as well as
autologous tumour cells.
There are numerous examples of CTL that are stimulated with
synthetic peptides (derived from the sequence of tumour antigens)
which are able to recognise and kill tumour cells effectively (for a
review, see Wang and Rosenberg, 1999). In prostate cancer, several
markers such as prostate-specific antigen, prostatic acid phospha-
tase, prostate stem cell antigen and prostate-specific membrane
antigen, which are all preferentially expressed by prostatic
epithelial cells, have been demonstrated to serve as substrate
sources of immunogenic peptide epitopes recognised by CTL
(Correale et al, 1998; Peshwa et al, 1998; Dannull et al, 2000; Lu
and Celis, 2002). HER-2/neu has also been identified to be
expressed on prostate cancer cells (Scher, 2000). Herein, we show
that one patient with prostate cancer developed increased CTL PF
for HER-2(9369), suggesting that this epitope is naturally processed
and expressed on prostate tumour cells. McNeel et al (2003)
vaccinated patients with advanced prostate cancer with the E75
HLA-A2 epitope from HER-2/neu (i.e., HER-2(9369)) using flt3
ligand as an adjuvant. Apart from a single patient (20 patients were
enrolled in their study), no significant peptide-specific T-cell
responses could be detected by ELISPOT. These data, although
demonstrating that only a minority of HLA-A2
þ prostate cancer
patients responded to this peptide, still do not exclude the
possibility that by using alternative immunisation protocols (e.g.,
injections with peptide-pulsed DC plus flt3 ligand) the number of
responders might be considerably increased.
In summary, we have evaluated HER-2(9369)-specific PF
in patients with five different types of cancer. Patients with
pre-existing immunity to this peptide have been scored, in
addition to breast and ovarian, also in colorectal, lung and, for
the first time, in prostate cancer, demonstrating that HER-2(9369)
is ideal for peptide-based vaccinations in these types of cancer.
Our unpublished observations that T cells from HLA-A2, A3 and
A26 patients with pre-existing immunity to HER-2(9369) could also
lyse their HER-2/neu
þ autologous tumours points to the fact that
this peptide is endogenously processed and presented in the
surface of tumours by any of the three alleles, thus increasing the
population of patients that can be enrolled in peptide-based
vaccinations.
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